Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | AGEN1571 |
| Trade Name | |
| Synonyms | AGEN 1571|AGEN-1571 |
| Drug Descriptions |
AGEN1571 is a human monoclonal antibody that targets ILT2, potentially leading to increased pro-inflammatory cytokine secretion, immune cell activation, and enhanced antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr 2906). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C188044 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| AGEN1571 | AGEN1571 | 0 | 1 |
| AGEN1571 + Balstilimab | AGEN1571 Balstilimab | 0 | 1 |
| AGEN1571 + Balstilimab + Botensilimab | AGEN1571 Balstilimab Botensilimab | 0 | 1 |
| AGEN1571 + Botensilimab | AGEN1571 Botensilimab | 0 | 1 |